Diadexus, Inc. Stock

DDXSQ

US25245P2056

Pharmaceuticals

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI

Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	49.2K 42.59K 39.81K 36.39K 68.57K 4.69M 69.64K 467K 183K 2.35M 185K 181K 7.82M	P/E 2014	-3.26x	P/E 2015	-1.14x
Enterprise Value	5.29M 4.58M 4.28M 3.91M 7.37M 505M 7.49M 50.2M 19.7M 252M 19.86M 19.43M 841M	EV / Sales 2014	1.05x	EV / Sales 2015	0.77x
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI
09/05/18	Motion for Asset Sale Filed by Diadexus, Inc.	CI
01/08/16	Diazyme Laboratories, Inc. completed the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
29/07/16	Motion for Asset Sale Approved for Diadexus, Inc.	CI
29/07/16	General Atomics Corp. entered into purchase agreement to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $4.8 million.	CI
20/07/16	Cleveland HeartLab, Inc. cancelled the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
07/07/16	Motion for Asset Sale Filed by Diadexus, Inc.	CI
07/07/16	Cleveland HeartLab, Inc. agreed to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $7 million.	CI
13/06/16	Diadexus, Inc. Filed for Bankruptcy	CI
10/06/16	Diadexus, Inc. Announces Resignation of Leone Patterson as Chief Financial Office	CI
23/05/16	Diadexus, Sonic Healthcare USA Sign National Agreement for PLAC Activity Test	CI
30/04/16	Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIADEXUS, INC.	-.--%	-.--%	-	-	410
ULTRAGENYX PHARMACEUTICAL INC.	+0.65%	+4.69%	-1.35%	-25.61%	2.63B
SAREPTA THERAPEUTICS, INC.	+4.19%	+9.09%	-0.33%	-83.45%	1.81B
BIONOTE, INC.	+1.14%	+7.22%	-7.02%	-13.43%	350M
DK LIFE SCIENCE CO., LTD.	+1.83%	+3.95%	-45.30%	-	56.39M
Average	+1.56%	+10.71%	-13.50%	-40.83%	970.98M
Weighted average by Cap.	+2.02%	+20.87%	-1.89%	-46.59%

	2014	2015
Net sales	26.11M 22.61M 21.13M 19.31M 36.39M 2.49B 36.96M 248M 97.22M 1.25B 98.05M 95.91M 4.15B	17.88M 15.48M 14.47M 13.23M 24.92M 1.71B 25.31M 170M 66.59M 853M 67.15M 65.69M 2.84B
Net income	-8.47M -7.33M -6.85M -6.26M -11.8M -808M -11.98M -80.34M -31.53M -404M -31.79M -31.1M -1.35B	-7.17M -6.2M -5.8M -5.3M -9.99M -683M -10.14M -68M -26.68M -342M -26.91M -26.32M -1.14B
Net Debt	-198K -171K -160K -146K -276K -18.88M -280K -1.88M -737K -9.45M -743K -727K -31.46M	5.24M 4.54M 4.24M 3.88M 7.3M 500M 7.42M 49.73M 19.51M 250M 19.68M 19.25M 833M

Diadexus, Inc. Stock

Stocks

DDXSQ

US25245P2056

Pharmaceuticals

Valuation: Diadexus, Inc.

Latest news : Diadexus, Inc.

Diagnostic & Testing Substances Manufacturers

Financials

Company Profile